Altimmune(NASDAQ) ALT

Altimmune, Inc. develops drugs to manage body weight and liver health. Its therapies aim to treat chronic infections and metabolic disorders. These medicines help patients through dual-action chemical processes in the body.

Focus on Obesity and Liver Health

• Pemvidutide: Investigational injectable medicine acting as a dual receptor agonist to treat obesity and liver inflammation; currently in late-stage clinical development.
• MASH Treatments: Therapeutic candidate targeting metabolic dysfunction-associated steatohepatitis, a liver disease marked by inflammation and cell damage; recently received Breakthrough Therapy Designation.
• Alcohol Use Treatments: Clinical-stage drug candidates designed to reduce alcohol consumption and liver damage in patients with alcohol use disorder or liver disease.
• HepTcell: Immunotherapy candidate in Phase 2 trials for patients living with chronic hepatitis B virus infections.

Strategic Moves and Clinical Trials

• Started the PERFORMA Phase 3 global clinical trial in August 2026 to evaluate pemvidutide for treating liver inflammation.
• Secured Breakthrough Therapy Designation from the FDA in January 2026 for the treatment of liver disease.
• Completed a public offering in April 2026 that raised approximately $211.1 million in net proceeds to fund operations.
• Announced plans in June 2026 to move corporate headquarters to Morristown, New Jersey, to access regional pharmaceutical talent.

What Makes the Science Different?

Altimmune focuses on dual-acting therapies that target both metabolic and inflammatory pathways in the body simultaneously. This approach allows a single medicine to address multiple conditions, such as weight loss and liver scarring, through a balanced chemical mechanism.

Measuring the Financial Progress

• Net loss was $45.4 million for the six-month period ended June 30, 2026, up 9% year over year.
• Research and development expenses reached $34.8 million for the six-month period ended June 30, 2026, up 5% year over year.
• Total cash, cash equivalents, and investments in marketable securities were $518.6 million as of June 30, 2026.
• General and administrative expenses were $15.6 million for the six-month period ended June 30, 2026, up 34% year over year.
• Market capitalization was $569.8 million according to the most recent company profile data.

Bottom Line

Altimmune has transitioned into a late-stage development company by advancing its dual-action drug candidates through critical clinical milestones. Its shift toward large-scale trials and a new regional hub reflects a focus on scaling its metabolic and liver disease programs.